DE60234015D1 - Latentes tuberkulose-diagnostisches antigen und verwendungsmethode - Google Patents

Latentes tuberkulose-diagnostisches antigen und verwendungsmethode

Info

Publication number
DE60234015D1
DE60234015D1 DE60234015T DE60234015T DE60234015D1 DE 60234015 D1 DE60234015 D1 DE 60234015D1 DE 60234015 T DE60234015 T DE 60234015T DE 60234015 T DE60234015 T DE 60234015T DE 60234015 D1 DE60234015 D1 DE 60234015D1
Authority
DE
Germany
Prior art keywords
latent tuberculosis
methods
use method
diagnostic antigen
tuberculosis diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234015T
Other languages
English (en)
Inventor
Frederick D Quinn
Kristin A Birkness
Manon Deslauriers
Peter King
David S Beall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60234015D1 publication Critical patent/DE60234015D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56955—Bacteria involved in periodontal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
DE60234015T 2001-01-08 2002-01-07 Latentes tuberkulose-diagnostisches antigen und verwendungsmethode Expired - Lifetime DE60234015D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26034801P 2001-01-08 2001-01-08
US31123501P 2001-08-09 2001-08-09
PCT/US2002/000309 WO2002054073A2 (en) 2001-01-08 2002-01-07 Latent human tuberculosis model, diagnostic antigens, and methods of use

Publications (1)

Publication Number Publication Date
DE60234015D1 true DE60234015D1 (de) 2009-11-26

Family

ID=26947939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234015T Expired - Lifetime DE60234015D1 (de) 2001-01-08 2002-01-07 Latentes tuberkulose-diagnostisches antigen und verwendungsmethode

Country Status (8)

Country Link
US (1) US7105170B2 (de)
EP (1) EP1360498B1 (de)
JP (1) JP3944452B2 (de)
AT (1) ATE445839T1 (de)
AU (1) AU2002237764B2 (de)
CA (2) CA2689741C (de)
DE (1) DE60234015D1 (de)
WO (1) WO2002054073A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
ES2231037B1 (es) * 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
NZ562142A (en) * 2005-03-31 2009-12-24 Univ Leiden Medical Ct Methods and means for diagnostics, prevention and treatment of Mycobacterium infections and tuberculosis disease
NZ597557A (en) 2006-03-02 2013-10-25 Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
AU2008245901B2 (en) * 2007-04-30 2014-10-16 University Of Central Florida Research Foundation, Inc. In vitro model of latent Mycobacterial infection
US8058022B2 (en) 2009-07-27 2011-11-15 Indian Institute Of Science Diagnosis and monitoring of mycobacterium tuberculosis infection
EP2807487B1 (de) * 2012-01-27 2017-11-29 PEAS Institut AB Verfahren zum nachweis von tuberkulose
EP2939025B1 (de) * 2012-12-28 2018-04-25 Cellestis Limited Zellvermittelter immunreaktionstest
KR101552610B1 (ko) 2013-09-24 2015-09-18 연세대학교 산학협력단 육아종 동물모델 및 그 제조방법
WO2016011280A1 (en) * 2014-07-16 2016-01-21 Tangen Biosciences, Inc. Isothermal methods for amplifying nucleic acid samples
EP3215260B1 (de) 2014-11-03 2020-01-15 Tangen Biosciences Inc. Vorrichtung und verfahren für zellen-, sporen- oder viruserfassung und unterbrechung
CN109030825A (zh) * 2017-06-12 2018-12-18 广东体必康生物科技有限公司 用于特异性检测结核分枝杆菌感染的蛋白Rv2031c
RU2702609C1 (ru) * 2018-08-06 2019-10-08 Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) Способ моделирования туберкулезной инфекции in vitro
WO2020264258A1 (en) * 2019-06-28 2020-12-30 United States Government As Represented By The Department Of Veterans Affairs Methods of producing granulomas and animal models of sarcoidosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1750197A (en) * 1996-01-17 1997-08-11 Trustees Of Boston University Mycobacterium antigens and methods for their detection
JP2000508525A (ja) * 1996-03-27 2000-07-11 ザ・ジョンズ・ホプキンス・ユニバーシティー マイコバクテリウム・チュバキュローシスの定常期ストレス応答σ因子およびその制御
US5700925A (en) 1996-03-27 1997-12-23 The Johns Hopkins University DNA encoding stationary phase, stress response sigma factor from Mycobacterium tuberculosis
US5824546A (en) 1996-03-27 1998-10-20 The Johns Hopkins University Regulation of a sigma factor from Mycobacterium tuberculosis
CA2276491C (en) * 1996-12-31 2008-01-22 New York University Early detection of mycobacterial disease
WO1999002670A1 (en) * 1997-07-10 1999-01-21 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP1029053A1 (de) * 1997-11-10 2000-08-23 Statens Seruminstitut Nukleinsäurefragmente und polypeptide von mycobacterium tuberculosis

Also Published As

Publication number Publication date
EP1360498B1 (de) 2009-10-14
WO2002054073A2 (en) 2002-07-11
JP3944452B2 (ja) 2007-07-11
EP1360498A2 (de) 2003-11-12
AU2002237764B2 (en) 2007-08-23
WO2002054073A3 (en) 2003-08-28
CA2433069C (en) 2010-03-30
US7105170B2 (en) 2006-09-12
ATE445839T1 (de) 2009-10-15
CA2433069A1 (en) 2002-07-11
US20040146933A1 (en) 2004-07-29
CA2689741C (en) 2013-10-01
CA2689741A1 (en) 2002-07-11
JP2005506512A (ja) 2005-03-03

Similar Documents

Publication Publication Date Title
DE60234015D1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
HUP0500444A2 (hu) HCV antigén/ellenanyag-kombinációs esszé
TW200512457A (en) Method of diagnosing SARS corona virus infection
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
HUP0303134A2 (hu) HIV-peptidek, antigének, vakcinakészítmények, immunológiai mérési reagenskészletek és eljárás HIV által indukált antitestek detektálására
DE602004020489D1 (de) Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von für antigene niedriger immunogenizität spezifischen monoklonalen antikörpern
EA200700345A1 (ru) Обогащённое антитело для выявления микобактериальной инфекции, способы применения и диагностические тесты, применяющие такое антитело
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
Whelan et al. Modulation of the bovine delayed-type hypersensitivity responses to defined mycobacterial antigens by a synthetic bacterial lipopeptide
BR0011449A (pt) Método para detectar sìfilis usando antìgenos sintéticos
WO2006138324A3 (en) Treponema pallidum antigens for vaccine development and diagnostic tests
ES2141348T3 (es) Metodo de deteccion de la presencia de una especie de mycobacterium, kit y anticuerpos utilizados en este metodo.
PT946874E (pt) Diagnostico de helicobacter pylori
DE602005026688D1 (de) Toleranzstudienverfahren bei mhc-ii-transgenen tieren
FI20012603A0 (fi) Diagnostinen menetelmä
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
ATE212129T1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
CA2276491A1 (en) Early detection of mycobacterial disease
BR0314166B8 (pt) teste de hcv
ATE403867T1 (de) Evaluierung adjuvanshaltiger impfstoffe
ATE429440T1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
NO20054142D0 (no) In vitro diagnostisk test for enterovirale infeksjoner
ATE206138T1 (de) Helicobacter pylori antigen
WO2003076570A3 (en) Antigens and their use as diagnostics and vaccines against species of plasmodium
JP7401457B2 (ja) ワクチンの効力を決定するための方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition